Samsung Biologics Q3 Operating Profit Rises 1% Year Over Year

Bitget2026/10/21 07:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Samsung Biologics’ third-quarter 2026 operating profit rose 1% year over year to KRW 640.1 billion.
Revenue increased 18.5% from a year earlier to KRW 1.49 trillion.
Net income fell 21.2% year over year to KRW 391.1 billion.
For the first nine months of 2026, revenue climbed 24.4% year over year to KRW 4.07 trillion.
Operating profit for that period grew 17.3% to KRW 1.81 trillion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261021800344), on October 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Samsung Biologics Q3 Operating Profit Rises 1% Year Over Year

You may also like

Crypto prices